The Royal Society (Investor) Non-funding Support

Entity: The Royal Society
Programme Title: ""COVID-19 Rapid Review Initiative""
Link: https://oaspa.org/wp-content/uploads/2020/05/COVID-19-WORKING-GROUP_v2.0.pdf
Contact (1): sarah.greaves@hindawi.com
Contact (2): phil.hurst@royalsociety.org

Summary:

https://researchsupport.admin.ox.ac.uk/funding/cross-publisher-covid-19-rapid-review-initiative
A group of publishers and scholarly communications organisations – initially comprising eLife, Hindawi, PeerJ, PLOS, Royal Society, F1000 Research, FAIRsharing, Outbreak Science, and PREreview – is working on initiatives and standards to speed up the review process while ensuring rigour and reproducibility remain paramount. The group has issued an open letter of intent and launched an initiative to ensure a rapid, efficient, yet responsible review of COVID-19 content.
The initiative is asking for volunteer reviewers with suitable expertise relevant to COVID-19, from all career stages and disciplines, to add their names to a 'rapid reviewer list'. By doing so, these reviewers will be committing to rapid reviewing times, and upfront agreement that their reviews and identity can be shared among participating publishers and journals if submissions get rerouted for any reason.

https://oaspa.org/covid-19-publishers-open-letter-of-intent-rapid-review/
https://oaspa.org/scholarly-publishers-working-together-during-covid-19-pandemic/
.
The Royal Society is funding parallel work developing data analysis methods for phase 3 in the project 'Bugbank'
http://www.bugbank.uk/

Bugbank: A project that aims to link infection data from Public Health England to improve the study of infection in the UK Biobank cohort.

Covid-19: In light of the ongoing pandemic, the systems we have put in place for Bugbank could be deployed to study Covid-19 infection caused by the novel coronavirus SARS-CoV-2 in near-to real time. The linkage of data between PHE and UKB may enable researchers around the world to look for genetic, epidemological and lifestyle risk factors for severe infection. This information could provide invaluable clues as to why some people develop mild symptoms while others develop life-threatening disease. The repurposing of phase 2 for studying Covid-19 is ongoing, with updates to follow here.
Technology: UK AgeTech 2020
Industry: AgeTech Investments
Headquarters: United Kingdom
Founded Date: N/A
Employees Number: N/A
Funding Status: N/A
Investor Type: N/A
Investment Stage: N/A
Number Of Exits: N/A

Visit Website
Undiscl@sed
Register and Claim Ownership